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Background: Obstetric hemorrhage is the leading cause of maternal mortality, particularly in low-resource settings
where women face significant delays in accessing definitive treatment. The Non-pneumatic Anti-Shock Garment
(NASG) is a first-aid device to stabilize women in hypovolemic shock secondary to obstetric hemorrhage. Prior
studies on the effectiveness of the NASG have suffered from small sample sizes and insufficient statistical power.
We sought to generate a summary effect estimate of this intervention by combining data from all previous
quasi-experimental studies.
Methods: Five quasi-experimental studies that tested the NASG as treatment for hypovolemic shock secondary to
obstetric hemorrhage at the tertiary care facility level were included in the analysis. We evaluated heterogeneity of
effect across studies and calculated pooled odds ratios. We also conducted a subgroup analysis among women in
the most severe condition.
Results: Participant characteristics were similar across studies with some variation in hemorrhage etiology. Median
blood loss was at least 50% lower in the intervention group than the control group. The pooled odds ratio
suggested that NASG intervention was associated with a 38% significantly reduced odds of mortality among the
overall sample, and a 59% significantly reduced odds of mortality among the most severe women.
Conclusions: The results from this combined analysis suggest that NASG intervention is associated with a reduced
odds of death for women with hypovolemic shock secondary to obstetric hemorrhage. Further research should
focus on application of the NASG at the community or primary health care level, and utilize a more robust
methodology.
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Obstetric hemorrhage (OH), including postpartum
hemorrhage (PPH), is the leading cause of maternal mor-
tality worldwide, particularly in low-resource settings
where access to blood and surgery are limited. About 30%
of direct maternal deaths are caused by OH, the vast ma-
jority of which occur in developing countries [1-3]. While
administration of prophylactic uterotonics reduces the risk
of atonic PPH by up to 60% [4-6], thousands of women
still experience PPH, and die without rapid recognition* Correspondence: elayadia@globalhealth.ucsf.edu
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reproduction in any medium, provided the orand treatment. Further, not all uterine atony will respond
to uterotonic treatment of PPH, and not all OH etiologies
will respond to uterotonics.
In low-resource settings, a series of delays contribute to
high maternal mortality: the decision to seek care, procur-
ing transport and reaching a Comprehensive Emergency
Obstetric Care (CEmOC) facility, and obtaining quality
definitive care [7]. One new low-technology first-aid de-
vice for stabilizing women suffering hypovolemic shock
secondary to obstetric hemorrhage is the Non-Pneumatic
Anti-Shock Garment (NASG), a lower-body compression
garment made of neoprene and Velcro™ (Zoex Corpor-
ation, Colma CA, USA; Figure 1). The NASG plays a
unique role in hemorrhage and shock management byl Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Non-pneumatic Anti-Shock Garment.
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ing the woman until definitive care is accessed.
Previous studies of the NASG at tertiary care facilities
have shown significantly reduced measured blood loss,
more rapid recovery from shock, and decreased mortal-
ity [8-12]. However, because mortality from obstetric
hemorrhage is rare, these studies have small sample sizes
and lack statistical power for some outcomes. These
same characteristics make conducting further studies
difficult and expensive. Therefore, we sought to combine
all the available data on NASG effectiveness, all of which
was conducted by our research group or our collaborators,
utilizing meta-analytic procedures to provide a summary
effect estimate.
Methods
Research on the NASG has been spearheaded by our re-
search group, the Safe Motherhood Program at the Uni-
versity of California, San Francisco (UCSF). Our research
program on the NASG is called Lifewrap (www.lifewrap.
org), and is a 501c3 educational organization. All of the
authors are employees of UCSF, and none has a financial
interest in the NASG product. We confirmed that no other
studies of the NASG existed in the literature by searching
electronic databases and relevant conference proceedings
utilizing the terms “non-pneumatic anti-shock garment”,
“anti-shock garment” and acronym, “NASG” through
August 31, 2012, and by conferring with researchers and
non-governmental organizations working with the NASG.
Our analysis comprised five quasi-experimental (non-ran-
domized) studies of the NASG as treatment for hypovol-
emic shock secondary to obstetric hemorrhage conducted
by our research group at UCSF or in conjunction withcollaborators: Miller 2006 in Egypt [8], Miller 2010 in
Egypt and Nigeria [12], Magwali 2012 in Lusaka, Zambia
and Harare, Zimbabwe [13]; Miller 2012 in Copperbelt,
Zambia [14]; and Maknikar 2012 in India [15]. We ex-
cluded one study, Jega 2012 in Nigeria, because there was
no comparison group [16]. Further articles identified re-
ferred to the aforementioned Miller 2006 [10] and Miller
2010 [9,17-21] studies. The methodological quality of the
five included studies was assessed. We also had access to
the full datasets for four of the five studies. Two of the in-
cluded trials were conducted within the same parent study
as preparatory phases for a cluster-randomized controlled
trial of the NASG (Magwali 2012, and Miller 2012) but
are presented separately in this review because the Miller
2012 site began 18 months later than Magwali 2012 and
had different characteristics.
All trials had a quasi-experimental design, utilizing a
pre-intervention phase followed by NASG intervention
phase, except for Maknikar 2012, which enrolled similar
individuals into control and treatment arms concurrently.
Eligibility criteria were similar across trials; women with
hypovolemic shock secondary to obstetric hemorrhage
from any etiology, an estimated blood loss of ≥750 mL
(Miller 2006 and Miller 2010) or ≥1000 mL (Magwali
2012, Miller 2012, and Maknikar 2012) and one or more
clinical signs of hypovolemic shock (systolic blood pres-
sure (SBP) ≤100 mmHg and/or pulse ≥100 beats per mi-
nute (BPM)). Standard protocols for hemorrhage and
shock were followed in both phases: administration of
crystalloid intravenous fluids and blood transfusion, use of
uterotonics, uterine massage, vaginal procedures, and sur-
gery. Mortality as outcome was reported for all studies.
Four studies reported blood loss measured by a closed-
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blood loss (Maknikar 2012).
The odds ratios and 95% confidence intervals were
calculated for each study, and meta-analytic procedures
were utilized in Stata (v.11, College Station, TX) to
synthesize a pooled odds ratio (POR) utilizing the
Mantel-Haenszel fixed effects method. This method was
chosen a priori because it is more robust for smaller
studies and low event rates, and the assumptions are
theoretically more appropriate for the NASG interven-
tion [22,23]. We tested for heterogeneity of effect using
the chi-square test for heterogeneity (Q statistic), using a
type 1 error threshold of 10% for statistical significance,
and evaluated the I2 value and 95% confidence interval
to quantify the degree of heterogeneity. We then con-
ducted a subgroup analysis among participants in the
most severe condition who entered the study uncon-
scious or with mean arterial pressure (MAP) <60 mmHgTable 1 Selected characteristics of study participants for stud
participants n = 3563
Miller 2006 Miller 2010
Control NASG Control NASG
n = 158 n = 206 n = 607 n = 835
Demographics
Age mean (SD) 27.3 (6.1) 27.4 (5.7) 29.0 (6.4) 29.3 (6.2)
Parity mean (SD) 2.2 (2.2) 1.8 (1.8) 3.2 (2.8) 3.3 (2.8)
Weeks pregnanta mean (SD) 37.9 (2.8) 38.1 (2.9) 37.4 (3.2) 37.6 (3.2)
Definitive diagnosis
Uterine atony 67 (43.0) 69 (33.5) 190 (31.3) 319 (38.2
Complications of abortion 25 (16.0) 35 (17.0) 45 (7.4) 93 (11.1)
Placenta previa 4 (2.6) 6 (2.9) 40 (6.6) 31 (3.7)
Placental abruption 4 (2.6) 11 (5.3) 79 (13.0) 98 (11.7)
Ectopic pregnancy 9 (5.8) 19 (9.2) 95 (15.7) 85 (10.2)
Molar pregnancy 3 (1.9) 5 (2.4) 7 (1.2) 11 (1.3)
Ruptured uterus 5 (3.2) 7 (3.4) 46 (7.6) 32 (3.8)
Placenta accreta 0 (0.0) 0 (0.0) 6 (1.0) 9 (1.1)
Lacerations/Genital trauma 15 (9.6) 29 (14.1) 25 (4.1) 65 (7.8)
Retained placenta 9 (5.8) 12 (5.8) 71 (11.7) 83 (9.9)
Other 15 (9.6) 13 (6.3) 3 (0.5) 9 (1.1)
Condition on study entry
Est. blood loss, median (IQR) 750 (750) 975 (750) 1000 (500) 1200 (500
Mean arterial pressure < 60 17 (10.8) 32 (16.0) 181 (29.9) 321 (38.5
Unconscious 2 (1.3) 7 (3.4) 27 (4.5) 41 (5.0)
Outcomes
Blood loss, median (IQR) 500 (450) 250 (400) 370 (550) 50 (175)
Mortality 2 (1.3) 0 (0.0) 38 (6.3) 29 (3.5)
aExcluding weeks pregnant ≤ 24 weeks.
bSome data not available from Maknikar 2012.[24]. Where heterogeneity of effect was statistically sig-
nificant, we evaluated a random effects model utilizing
the DerSimonian and Laird procedure [25]. We also
conducted a sensitivity analysis for the overall sample
and subsamples by estimating pooled effect estimates,
sequentially excluding each study to assess whether re-
sults obtained in the primary analysis were robust to the
exclusion of particular studies.
Results
Characteristics of the five trials are presented in Table 1.
Trail size ranged from 260 (Maknikar 2012) to 1442 total
participants (Miller 2010) representing 3,563 participants;
1616 received NASG treatment plus standard OH care
(45.4%) and 1947 received standard OH care only (54.6%).
The mean age of participants was 28.1 (range: 26.3 – 29.3)
and mean parity was 2.7 (range 1.8 – 3.3). Four studiesies included in combined analysis of NASG, all study
Magwali 2012 Miller 2012 Maknikar 2012b
Control NASG Control NASG Control NASG
n = 469 n = 306 n = 574 n = 148 n = 139 n = 121
28.0 (6.1) 27.9 (6.3) 26.7 (6.9) 26.5 (6.9)
2.2 (1.7) 2.4 (1.9) 2.3 (2.2) 2.2 (2.1)
36.7 (3.8) 37.2 (3.5) 36.3 (2.8) 36.4 (2.7)
) 92 (19.6) 65 (21.2) 68 (11.8) 21 (14.2)
146 (31.1) 89 (29.1) 95 (16.6) 26 (17.6)
16 (3.4) 12 (3.9) 33 (5.8) 4 (2.7)
45 (9.6) 30 (9.8) 36 (6.3) 8 (5.4)
26 (5.5) 9 (2.9) 20 (3.5) 7 (4.7)
2 (0.4) 2 (0.7) 3 (0.5) 0 (0.0)
30 (6.4) 16 (5.2) 19 (3.3) 5 (3.4)
2 (0.4) 2 (0.7) 3 (0.5) 2 (1.4)
26 (5.5) 14 (4.6) 166 (28.9) 38 (25.7)
82 (17.5) 64 (20.9) 127 (22.1) 36 (24.3)
2 (0.4) 2 (0.7) 4 (0.7) 0 (0.0)
) 1000 (850) 1000 (850) 700 (500) 781 (700)
) 188 (40.1) 158 (51.6) 150 (26.1) 42 (28.4)
6 (1.3) 12 (3.9) 1 (0.2) 1 (0.7) 14 (10.1) 10 (8.3)
500 (550) 150 (200) 480 (450) 400 (370)
13 (2.8) 5 (1.6) 9 (1.6) 5 (3.4) 35 (28.9) 27 (19.4)
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across studies, but were largely postpartum etiologies or
complications of abortion. Median estimated blood loss at
study entry ranged from 700 – 1200 mLs. The proportion
with MAP < 60 varied across studies, from 13.5% (Miller
2006) to 44.6% (Magwali 2012).
Four studies reported blood loss measured by a
closed-end calibrated plastic drape. In three of these
sites, median measured blood loss value was reduced by
50% or more in the NASG intervention group versus the
control group. While the Miller 2006, Miller 2010 and
Magwali 2012 trials all reported such decline, the me-
dian measured blood loss in Miller 2012 represented a
smaller decrease across study arms. Maknikar 2012 did
not report blood loss.
All five studies presented odds ratios for the effect of
NASG intervention on mortality (Figure 2). In four of
the studies, NASG intervention was associated with a re-
duced odds of mortality (OR range 0.15 – 0.59), how-
ever, this effect reached statistical significance for only
one study (Miller 2010) [12]. Results from Miller 2012
were not consistent with this pattern; for this study,
NASG intervention was associated with a two-fold in-
creased odds of mortality. However, this finding was not
statistically significant (OR 2.20, 95% CI 0.72 – 6.65).
Across the five studies significant heterogeneity of effect
was not identified (Q 6.16, p = 0.187), and the I2 esti-
mate was also not significant (95% CI 0 – 76). Among
the 3,563 women included in the five studies, the POR
for mortality was 0.62 (95% CI 0.44 – 0.86), suggesting
that NASG treatment was associated with a 38% signifi-
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Figure 2 Forest plot describing odds ratios for mortality from hypovo
intervention phase vs. control phase, all study participants (n=3563).Subanalysis of women with most severe shock
Across the studies, 1,229 women were considered to be in
the most severe condition, defined as MAP < 60 mmHg
or unconscious on study entry (Table 2). Fifty-two percent
(51.7%) received the NASG plus standard OH care while
48.3% received standard OH care only. The characteristics
of the subsample were largely similar to the overall sam-
ple, however estimated blood loss at study entry appeared
slightly higher. In three of the four studies that reported
blood loss, median measured blood loss was reduced by at
least 55% in the NASG intervention phase compared to
the control phase. The difference in median measured
blood loss between intervention groups in the Miller 2012
study was much smaller. Effect estimates from the studies
largely indicate a protective effect of the NASG on mortal-
ity, with odds ratios ranging from 0.16 – 0.38 (Figure 3),
and two of the studies reached statistical significance
(Miller 2010, and Maknikar 2012). Again, the result from
Miller 2012 study was inconsistent with the other studies
(OR 2.81, 95% CI 0.60 – 13.07). The Q statistic suggested
significant heterogeneity of effect across studies (Q 7.95,
p = 0.092) using a conservative threshold. The POR utiliz-
ing a random effects model was 0.41 (95% CI 0.20 – 0.83),
indicating that NASG treatment was associated with a
59% reduced odds of mortality from obstetric hemorrhage
among the women with the most profound shock.
Sensitivity analyses
The POR calculated through sequentially excluding one
trial from the analysis ranged from POR 0.55 (0.39 – 0.78)
when Miller 2012 was excluded to POR 0.69 (0.44 – 1.08)









lemic shock secondary to obstetric hemorrhage in NASG
Table 2 Selected characteristics of study participants for studies included in combined analysis of NASG, participants
in most severe shock n = 1,229
Miller 2006 Miller 2010 Magwali 2012 Miller 2012 Maknikar 2012b
Control NASG Control NASG Control NASG Control NASG Control NASG
n = 18 n = 35 n = 183 n = 327 n = 190 n = 162 n = 150 n = 42 n = 53 n = 69
Demographics
Age mean (SD) 25.9 (5.3) 26.9 (5.8) 30.1 (6.5) 30.2 (6.3) 28.3 (5.8) 28.0 (6.0) 26.7 (6.9) 26.8 (7.0)
Parity mean (SD) 2.6 (2.5) 1.5 (1.8) 4.8 (3.1) 4.4 (3.3) 2.4 (1.8) 2.4 (1.9) 2.3 (2.2) 2.3 (2.0)
Weeks pregnant a, mean (SD) 38.4 (3.1) 39.2 (1.2) 37.7 (2.8) 37.1 (3.2) 36.7 (3.7) 37.4 (3.4) 36.3 (2.7) 36.4 (3.0)
Definitive diagnosis
Uterine atony 7 (38.9) 12 (34.3) 57 (31.2) 79 (24.2) 28 (14.7) 31 (19.1) 20 (13.3) 6 (14.3)
Complications of abortion 3 (16.7) 9 (25.7) 12 (6.6) 36 (11.0) 67 (35.3) 50 (30.9) 31 (20.7) 14 (33.3)
Placenta previa 1 (5.6) 0 (0.0) 11 (6.0) 22 (6.7) 4 (2.1) 6 (3.7) 10 (6.7) 0 (0.0)
Placental abruption 2 (11.1) 0 (0.0) 19 (10.4) 49 (15.0) 13 (6.8) 13 (8.0) 6 (4.0) 2 (4.8)
Ectopic pregnancy 0 (0.0) 9 (25.7) 17 (9.3) 26 (8.0) 14 (7.4) 2 (1.2) 4 (2.7) 5 (11.9)
Molar pregnancy 0 (0.0) 1 (2.9) 1 (0.6) 6 (1.8) 1 (0.5) 0 (0.0) 2 (1.3) 0 (0.0)
Ruptured uterus 2 (11.1) 1 (2.9) 20 (10.9) 19 (5.8) 14 (7.4) 7 (4.3) 2 (1.3) 2 (4.8)
Placenta accreta 0 (0.0) 0 (0.0) 4 (2.2) 5 (1.5) 1 (0.5) 1 (0.6) 2 (1.3) 1 (2.4)
Lacerations/Genital trauma 1 (5.6) 1 (2.9) 4 (2.2) 24 (7.3) 10 (5.3) 6 (3.7) 31 (20.7) 3 (7.1)
Retained placenta 0 (0.0) 1 (2.9) 38 (20.8) 56 (17.1) 37 (19.5) 44 (27.2) 39 (26.0) 9 (21.4)
Other 2 (11.1) 1 (2.9) 0 (0.0) 3 (0.9) 1 (0.5) 1 (0.6) 3 (2.0) 0 (0.0)
Condition on study entry
Est. blood loss, median (IQR) 1500 (750) 1500 (1150) 1500 (1000) 1500 (800) 1000 (800) 1000 (500) 700 (500) 800 (700)
Mean arterial pressure < 60 17 (94.4) 30 (93.8) 181 (98.9) 321 (98.2) 188 (99.0) 158 (97.5) 150 (100.0) 42 (100.0)
Unconscious 2 (11.1) 6 (18.2) 27 (15.1) 41 (12.9) 6 (3.2) 12 (7.4) 1 (0.7) 1 (2.4) 53 (100.0) 69 (100.0)
Outcomes
Blood loss median (IQR) 555 (700) 250 (350) 360 (500) 55 (175) 600 (520) 150 (200) 480 (480) 430 (370)
Mortality 1 (5.6) 0 (0.0) 34 (18.6) 26 (8.0) 10 (5.3) 2 (1.2) 4 (2.7) 3 (7.1) 31 (58.5) 19 (27.5)
aExcluding weeks pregnant ≤ 24 weeks.
bSome data not available from Maknikar 2012.
El Ayadi et al. BMC Pregnancy and Childbirth 2013, 13:208 Page 5 of 8
http://www.biomedcentral.com/1471-2393/13/208Similar results were observed for the subgroup of women
with severe shock, where the most protective effect esti-
mate was observed when excluding Miller 2012 (POR
0.32, 95% CI 0.21 – 0.49), ranging through POR 0.51
(0.17 – 1.49) where Maknikar 2012 was excluded.Discussion
Overall the combined results and pooled effect estimates
from this combined analysis suggest that NASG inter-
vention at tertiary facilities is associated with a reduced
odds of death for women with hypovolemic shock sec-
ondary to obstetric hemorrhage. For all women we ob-
served a statistically significant 38% reduction in the
odds of death, and for women in the most severe shock
we observed a 59% protective effect. The studies in-
cluded in the review all had similar design, intervention,
and eligibility criteria. Small differences were observed
in the distribution of hemorrhage etiology.Across the included studies, the outcomes of measured
blood loss and mortality were different for Miller 2012
compared to the other four trials. The authors had some
reservations about including this trial into the analysis
due to quality concerns expressed by the research team.
During the pre-intervention phase there was over-
enrollment of mild cases. A review of all facility-based
OH-related maternal deaths revealed that the proportion
of actual maternal deaths enrolled in the study was low
and varied by intervention phase. During the control
phase, 37.5% of actual OH-related maternal deaths were
captured by the study, whereas in the intervention
phase, 60.5% of these deaths were captured. It is there-
fore not surprising that excluding Miller 2012 during the
sensitivity analysis revealed the strongest effect for the
NASG intervention: POR 0.55 (95% CI 0.39 – 0.78)
among the full sample and POR 0.32 (95% CI 0.21 –
0.49) for women in the most severe shock. We chose
not to exclude this particular trial because the results
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Figure 3 Forest plot describing odds ratios for mortality from hypovolemic shock secondary to obstetric hemorrhage in NASG
intervention phase vs. control phase, study participants in most severe shock (n=1229).
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estimate of the NASG under certain conditions of use.
While the results of this analysis suggest a reduction
in the odds of mortality associated with NASG interven-
tion, it is important to consider the specific methodological
decisions that went into this analysis. Our protocol defined
a 10% type error rate as the threshold for considering
whether heterogeneity of effect existed across the findings
from the component studies. The Q statistics generated
from our models indicated that results were not signifi-
cantly heterogenous for the overall sample (p = 0.187), but
that they were for the subsample of women in the most se-
vere shock (p = 0.092). Thus, the analysis method differed
across the samples; we utilized a fixed effect method for
the overall sample and a random effect method for the
subsample. The threshold that we utilized to determineTable 3 Sensitivity analysis: pooled odds ratios for
mortality from hypovolemic shock secondary to obstetric
hemorrhage in NASG intervention phase versus control
phase, sequentially removing one study from pooled
analysis, for all study participants (n = 3563) and study
participants in most severe shock (n = 1229)
Excluded study All Participants Most severe shock
OR 95% CI OR 95% CI
Miller 2006 0.63 0.45 – 0.88 0.43 0.20 – 0.94
Miller 2010 0.69 0.44 – 1.08 0.45 0.13 – 1.55
Magwali 2012 0.62 0.44 – 0.88 0.47 0.20 – 1.09
Miller 2012 0.55 0.39 – 0.78 0.32 0.21 – 0.49
Maknikar 2012 0.63 0.42 – 0.95 0.51 0.17 – 1.49
Combined 0.62 0.44 – 0.86 0.41 0.20 – 0.84significant heterogeneity was conservative, however, it
could be argued that a more conservative approach was
warranted for this analysis due to the small number of in-
dividual studies trialing the NASG and the increased likeli-
hood of committing a type II error for the Q and I2
statistics [26,27]. Such an approach could have included
pursuing a random-effects analysis of the overall sample;
we explored the random-effects analysis and while the
findings from this analysis were similar in their clinical sig-
nificance, the wider confidence interval was not statistically
significant (POR 0.66, 95% CI 0.41 – 1.07). However, inter-
pretation of these results should take into consideration
the assumptions inherent to each of these methods and
the quality concerns around the one study that is respon-
sible for the observed heterogeneity of effect. Furthermore,
sensitivity analyses demonstrated the pooled effect esti-
mates and their confidence intervals for both fixed and
random methods to be equal and support a statistically sig-
nificant reduction in odds of mortality when excluding this
study from the analysis (not shown).
Strengths of this combined analysis include the com-
prehensive inclusion of NASG tertiary facility trials; be-
cause the research team is the only known group to
have conducted any evaluations of the NASG to date,
and the only known group to provide technical assist-
ance and training to groups adopting the NASG into
their obstetric hemorrhage protocols, we feel relatively
confident that there are no trials missing from this ana-
lysis. Furthermore, inclusion and exclusion criteria are
consistent across studies, and all studies utilized the
same comparison groups of NASG plus standard care
for OH versus standard care for OH only. Finally, we did
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lished, allowing for inclusion of more data; three trials
whose results were peer-reviewed for presentation at
conferences were included.
The primary limitation of this analysis is that the data
do not come from randomized controlled trials, but ob-
servational studies. Furthermore, there are very few trials
that have been conducted utilizing the NASG, and the
trials that have been conducted are small and contain
few deaths. Because all trials have been implemented by
the same group (UCSF) or in collaboration with this
group, it is possible that any small but systematic biases
present across these studies may have become exagger-
ated within our pooled effect estimates. Additionally,
three of the five studies included in the combined ana-
lysis were not peer-reviewed full manuscripts; they were
presented solely at a conference. There were minimal
differences in populations across trials in terms of par-
ticipant’s characteristics at baseline or the variations in
hemorrhage etiologies.Conclusions
While these results support implementation of the NASG
in tertiary care facilities where women continue to suffer
from delays in receiving definitive treatment, it is likely
that the NASG may decrease mortality if applied at the
community or primary health care level before transfer to
the referral/tertiary-facility. The introductory phases of
the Magwali 2012 and Miller 2012 trials included in this
analysis were implemented in preparation for a cluster
randomized controlled trial (CRCT), a more robust meth-
odology, set in primary health care centers conducted
from June 2007 through May 2012. In conjunction with
the results presented in this analysis, the findings from
the CRCT and any subsequent robust studies will help
researchers and clinicians to better understand the utility
of the NASG in preventing mortality from hypovolemic
shock secondary to obstetric hemorrhage at different levels
of the health care system.
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